About P&T JournalContacts:
Editorial: Sonja Sherritze, Editor
Advertising: Maureen Dwyer Liberti,
Vice President, Group Publisher
Production: Mary Ellen Curry,
Director of Production Services
Circulation: Jackie Ott, Circulation Manager
Statement of Purpose
Guidelines for Authors
157th Annual Meeting of the American Psychiatric Association: Psychotherapy and Psychopharmacology — Dissolving the Mind–Brain Barrier
The author summarizes a few of the many sessions attended by more than 25,000 mental health professionals, specifically, the effect of medications on cholesterol levels as well as advances in pharmacotherapy for attention-deficit/hyperactivity disorder, major depression, and Alzheimer’s disease.
Reuben B. David
Dr. Wool compares the features of traditional Medicare with the new prescription drug coverage, as outlined in the Medicare Modernization Act of 2003, and emphasizes the need to continue working to improve the program.
Marvin S. Wool, MD, MPH
CONTINUING EDUCATION CREDIT
The author reviews the efficacy of beta blockade for patients undergoing noncardiac surgery who are at risk for myocardial infarction, unstable angina, congestive heart failure, and cardiac death.
Andrew D. Auerbach, MD, MPH
Patient Advocates Call for Greater Responsibility and Safety Measures in Hospitals: Medical Errors Still Rampant
A worthwhile book provides real-life examples of serious medical errors and stresses the need for more safeguards to prevent them from occurring.
David Nash, MD, MBA, discusses a new Web site that provides educational materials on diabetes for health care professionals, P&T committee members, and the public.
Stephen Barlas discusses “ protected” electronic health information and the efforts of employers to secure data in compliance with HIPAA requirements.
Matthew Grissinger, RPh, FASCP, reviews the pitfalls of automatic stop-order policies.
Matthew Grissinger, RPh, FASCP
P&T presents the latest studies and information about FDA approvals, drug indications, industry updates, and new devices.
The authors review transdermal oxybutynin (Oxytrol®) for the treatment of overactive bladder.
Vitalina Rozenfeld, PharmD, BCPS, Stanley Zaslau, MD, Kathleen New Geissel, PharmD, David Lucas, PhD, and Lili Babazadeh, PharmD